"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 7 | 1 | 8 |
| 1994 | 12 | 2 | 14 |
| 1995 | 5 | 2 | 7 |
| 1996 | 13 | 2 | 15 |
| 1997 | 8 | 1 | 9 |
| 1998 | 23 | 7 | 30 |
| 1999 | 9 | 9 | 18 |
| 2000 | 17 | 7 | 24 |
| 2001 | 25 | 6 | 31 |
| 2002 | 37 | 12 | 49 |
| 2003 | 32 | 12 | 44 |
| 2004 | 38 | 13 | 51 |
| 2005 | 34 | 19 | 53 |
| 2006 | 38 | 20 | 58 |
| 2007 | 49 | 18 | 67 |
| 2008 | 35 | 18 | 53 |
| 2009 | 44 | 25 | 69 |
| 2010 | 58 | 28 | 86 |
| 2011 | 64 | 19 | 83 |
| 2012 | 55 | 26 | 81 |
| 2013 | 54 | 24 | 78 |
| 2014 | 70 | 23 | 93 |
| 2015 | 78 | 32 | 110 |
| 2016 | 60 | 30 | 90 |
| 2017 | 53 | 25 | 78 |
| 2018 | 43 | 25 | 68 |
| 2019 | 44 | 23 | 67 |
| 2020 | 33 | 17 | 50 |
| 2021 | 42 | 14 | 56 |
| 2022 | 18 | 2 | 20 |
| 2023 | 27 | 0 | 27 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 Nov 14; 7(21):6492-6505.
-
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource. Mol Cancer Ther. 2023 Nov 01; 22(11):1270-1279.
-
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. JCO Precis Oncol. 2023 Sep; 7:e2300235.
-
Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.
-
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). Oncologist. 2023 08 03; 28(8):722-729.
-
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023 08; 12(15):15769-15776.
-
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023 07 11; 7(13):2983-2993.
-
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. 2023 06 01; 108(6):1567-1578.
-
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2023 06 01; 29(11):2052-2065.
-
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 06; 7:e2300041.